Western blot analysis of whole cell lysates from NIH/3T3 cells treated with calyculin A, using Phospho-beta-Catenin (Ser33/37/Thr41) Antibody #9561 alone (left) and the same antibody preincubated with Phospho-beta-Catenin (Ser33/37/Thr41) Blocking Peptide (right).Learn more about how we get our images
This peptide is used to block Phospho-beta-Catenin (Ser33/37/Thr41) Antibody # 9561 reactivity.
The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks Phospho-beta-Catenin (Ser33/37/Thr41) Antibody #9561 signal completely in Western blotting.
For Western immunoblotting, add 10 µl of antibody and 10 µl of blocking peptide to 10 ml of antibody dilution buffer, and incubate at room temperature for 2 hours before allowing to react with the blot.
Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. Store at –20°C.
β-Catenin is a key downstream effector in the Wnt signaling pathway (1). It is implicated in two major biological processes in vertebrates: early embryonic development (2) and tumorigenesis (3). CK1 phosphorylates β-catenin at Ser45. This phosphorylation event primes β-catenin for subsequent phosphorylation by GSK-3β (4-6). GSK-3β destabilizes β-catenin by phosphorylating it at Ser33, Ser37, and Thr41 (7). Mutations at these sites result in the stabilization of β-catenin protein levels and have been found in many tumor cell lines (8).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.